Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

State Legislative Issues to Watch in 2022

Joseph Cantrell, JD  |  January 7, 2022

States increasingly take the lead on issues critical to our members and the field of rheumatology, including copay accumulator bans, white bagging restrictions, prior authorization and drug pricing.

Filed under:Legislation & Advocacy Tagged with:copay accumulatorsLegislation & Advocacypharmacy benefit managers (PBMs)prior authorizationstate legislationwhite bagging

Tocilizumab Promising for the Treatment of Polymyalgia Rheumatica

Michele B. Kaufman, PharmD, BCGP  |  January 1, 2022

In a study, patients with new-onset polymyalgia rheumatica (PMR) who were treated with subcutaneous tocilizumab were more likely to achieve sustained, glucocorticoid-free remission than patients who received placebo.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports

New Healthcare Price Transparency Requirements Are Complicated & Vary by State

Emily A. Johnson, JD  |  December 16, 2021

Healthcare law is ever changing, particularly with regard to price transparency. Key healthcare leaders and stakeholders have long argued for more stringent price transparency regulations in an effort to increase patient awareness regarding the cost of a hospital item or service prior to receiving the service. Such information is anticipated to enable patients to take…

Filed under:Billing/CodingLegal UpdatesPractice Support Tagged with:healthcare price transparency

A positron emission tomography (PET) scan shows a 3 cm, hypermetabolic mass adjacent to the stomach.

Case Report: Elevated Inflammatory Markers & a Hypermetabolic Mass

Lisa L. Korn, MD, PhD, Mina L. Xu, MD, & Cristina Brunet, MD  |  December 16, 2021

Consulting rheumatologists often assess patients with atypical clinical presentations for the possibility of an underlying rheumatic disease. Inflammatory syndromes that are not clearly rheumatic in nature can be particularly challenging to diagnose. Here, we share the case of a young woman with a long-standing undiagnosed illness and highly elevated inflammatory markers, and describe the evaluation…

Filed under:Conditions Tagged with:Castleman's diseasemultidisciplinary care

Vax Hesitancy? Myths & Facts for Patients

Susan Bernstein  |  December 16, 2021

Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

Filed under:Patient Perspective Tagged with:COVID-19vaccinationvaccine hesitancy

New Booklet Offers Tips for Diagnosing Lupus, Images of Presentation on Skin of Color & More Insights

Renée Bacher  |  December 16, 2021

For decades, rheumatologist Cindy Flower, MD, accumulated images of systemic lupus erythematosus (SLE) in her patients, as well as clinical vignettes to use in teaching at Queen Elizabeth Hospital in Bridgetown, Barbados. For decades, she has wanted to do something wide-reaching with these materials, sharing information from her practice and her mentor, the late Prof….

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:general practitioners

The 2021 ACR Awards of Distinction & Distinguished Fellows

Patrice Fusillo  |  December 16, 2021

During ACR Convergence 2021 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care, announcing the recipients of the ACR’s 2021 Awards of Distinction, as well as the group of Distinguished Fellows. recognized for their contributions. Three pediatric rheumatologists and one pediatric fellow…

Filed under:AwardsProfessional Topics Tagged with:Dr. Alfredo AguirreDr. Alisa A. MuellerDr. Amanda E. NelsonDr. Anne R. BassDr. Brian M. FeldmanDr. Bryce A. BinstadtDr. Ida Dzifa DeyDr. Jacqueline MadisonDr. Jose U. ScherDr. Madelaine “Mattie” FeldmanDr. Mariana J. KaplanDr. Maximilian F. KonigDr. Michael H. WeismanDr. Naomi J. PatelDr. Philip SeoDr. Richard K. VeheDr. Rochelle L. CastilloDr. Roseanne F. ZhaoDr. Seoyoung C. KimDr. Sokratis ApostolidisDr. Stanley B. Cohen

Alpha Tauri 3D Graphics / shutterstock.com

Rheumatic Complications from Immune Checkpoint Inhibitors

Nilasha Ghosh, MD, MS, & Anne R. Bass, MD  |  December 16, 2021

Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…

Filed under:Conditions Tagged with:immune checkpoint inhibitor (ICI)immune-related adverse events

The Transformative Power of Tragedy

Philip Seo, MD, MHS  |  December 16, 2021

On Sept. 11, 2001, I was at work. I had accepted a position as an assistant chief of service (ACS) for the Department of Medicine, which is Hopkins-speak for a hybrid position that involves all the administrative duties of a chief resident, plus the responsibility of an attending. For a year, I admitted patients to…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19

FDA Authorizes New Long-Acting, Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals

U.S. Food & Drug Administration   |  December 13, 2021

On Dec. 8, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). The product…

Filed under:Drug Updates Tagged with:AstraZenecacilgavimabCOVID-19EvusheldFDAmonoclonal antibodytixagevimabU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 55
  • 56
  • 57
  • 58
  • 59
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences